FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors



Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12014031197710/23/14 new patent  Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
22014028813309/25/143 -amino- pyrazole derivatives useful against tuberculosis
32014022725908/14/14Modified proteins and peptides
42014022726408/14/14Drug fusions and conjugates with extended half life
52014020560407/24/14Antigen binding constructs
62014020566107/24/14Formulation for retinoid-containing soft gelatin capsules
72014020021807/17/14Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
82014019340707/10/14Drug fusions and conjugates
92014018775007/03/14Methods for selecting protease resistant polypeptides
102014017971506/26/142,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
112014015870406/12/14Medicament dispenser
122014014099605/22/14Anti-serum albumin biding variable domains
132014014099605/22/14Anti-serum albumin biding variable domains
142014011643405/01/14Dry powder inhaler compositions
152014011643405/01/14Dry powder inhaler compositions
162014011292904/24/14Tumour necrosis factor receptor 1 antagonists
172014011388804/24/14Novel combination of therapeutic agents
182014011392204/24/14Compounds
192014011292904/24/14Tumour necrosis factor receptor 1 antagonists
202014011388804/24/14Novel combination of therapeutic agents
212014011392204/24/14Compounds
222014010589404/17/14Humanized anti-il-18 antibodies
232014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
242014010589404/17/14Humanized anti-il-18 antibodies
252014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
262014007631403/20/14Manifold for use in medicament dispenser
272014008086303/20/14Muscarinic acetylcholine receptor antagonists
282014007631403/20/14Manifold for use in medicament dispenser
292014008086303/20/14Muscarinic acetylcholine receptor antagonists
302014005690002/27/14Method for inhibiting binding to b-cell receptor
312014005810502/27/14Substituted diketopiperazines and their use as oxytocin antagonists
322014005071902/20/14Antibodies
332014005172002/20/14N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
342014003898902/06/14Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
352014002359601/23/14Novel composition
362014002455801/23/14Method of treatment
372014000517701/02/14Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
382014000518801/02/14Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
392013034546512/26/13Process for the preparation of retigabine
402013033698912/19/13Methods of identifying a patient population
412013031590111/28/13Novel uses
422013031704111/28/13Compounds
432013031028111/21/13Novel antigen binding proteins
442013030233511/14/13Ligands that bind tgf-beta receptor ii
452013026771710/10/13Process for the preparation of atovaquone
462013026118510/03/13Benzamide derivatives as ep4 receptor agonists
472013025172409/26/13Antigen binding proteins to oncostatin m (osm)
482013025318809/26/13Novel compounds
492013023750109/12/13Benzofuran compounds for the treatment of hepatitis c virus infections
502013022420408/29/13Method of treatment based on atad2 inhibitors
512013022420408/29/13Method of treatment based on atad2 inhibitors
522013021315408/22/13Method of determining cleanliness
532013021339408/22/13Dispensing device
542013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
552013021315408/22/13Method of determining cleanliness
562013021339408/22/13Dispensing device
572013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
582013021089208/15/13Method of treatment
592013021089208/15/13Method of treatment
602013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
612013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
622013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
632013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
642013019641208/01/13Magi polynucleotides, polypetides, and antibodies
652013019641208/01/13Magi polynucleotides, polypetides, and antibodies
662013018925507/25/13Fusions and conjugates of insulinotropic agents
672013018925507/25/13Fusions and conjugates of insulinotropic agents
682013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
692013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
702013011813205/16/13Machine and method for pharmaceutical and pharmaceutical-like product assembly
712013011813205/16/13Machine and method for pharmaceutical and pharmaceutical-like product assembly
722013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
732013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
742013010278304/25/13Substituted diketopiperazines and their use as oxytocin antagonists
752013007819803/28/13Novel use
762013005337502/28/13Amino-quinolines as kinase inhibitors
772013003947002/14/13Sample plate for an x-ray powder diffraction apparatus
782013004098402/14/137-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
792013003001201/31/13Compounds
802013003001501/31/13Muscarinic acetylcholine receptor antagonists
812013002354101/24/13Voltage-gated sodium channel blockers
822013001249101/10/13Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
832012031620212/13/12Compounds which have activity at m1 receptor and their uses in medicine
842012030972512/06/12Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
852012030978912/06/12Compounds which have activity at m1 receptor and their uses in medicine
862012028854411/15/12Novel retigabine composition
872012027727911/01/12Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
882012025146810/04/12Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
892012024074209/27/12Novel device
902012024517109/27/12Benzpyrazole derivatives as inhibitors of pi3 kinases
912012023855909/20/12Novel compounds
922012023857109/20/12Indazole derivatives as pi 3-kinase
932012023206109/13/12Novel compounds
942012020774908/16/12Dosing regimen
952012020281108/09/12Novel compounds
962012015744606/21/12Medical use
972012015749106/21/12Muscarinic acetylcholine receptor antagonists
982012015749206/21/12Antibiotic drug
992012014971106/14/12Piperidine derivatives used as orexin antagonists
1002012014973106/14/12New medical use
1012012012868905/24/12Anti-il-23 immunoglobulins
1022012012977805/24/12Ligand that bind tgf-beta receptor rii
1032012011464705/10/12 anti-serum album single variable domains
1042012010013704/26/12Immunoglobulins
1052012010108304/26/12S1p1 agonists comprising a bicyclic n-containing ring
1062012010108604/26/12Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
1072012010112404/26/121,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
1082012010113404/26/125-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
1092012010113604/26/125-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
1102012006517703/15/12Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1112012005896303/08/12Macrolides with anti-inflammatory activity
1122012004625802/23/12Novel crystalline pharmaceutical product
1132012004646902/23/12Process for the preparation of a biphenyl-2-yl carbamic acid ester
1142012003982002/16/12Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1152012004099102/16/123-azabicyclo [4.1.0] heptanes used as orexin antagonists
1162012004102702/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1172012004102802/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1182012003431202/09/124-isopropyl-3-methylphenol for the treatment of inflammation
1192012000632201/12/12Drug dispenser
1202012000422901/05/12Substituted diketopiperazines and their use as oxytocin antagonists
1212011031937112/29/11Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1222011030569212/15/11Antigen-binding contructs
1232011030569312/15/11Anitigen-binding constructs
1242011028809811/24/11Novel compounds
1252011028190911/17/11Substituted quinoline derivatives as h1 receptor antagonists
1262011027565511/10/11Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1272011027566111/10/11Tricyclic nitrogen compounds used as antibacterials
1282011026973811/03/11Compounds
1292011026997011/03/11Phenethanolamine derivatives for treatment of respiratory diseases
1302011026358810/27/11Tricyclic compounds as glutamate receptor modulators
1312011025375210/20/11Nozzle for a nasal inhaler
1322011025607410/20/11Novel use
1332011024547010/06/11Immunoglobulins
1342011023779209/29/11Quinoline derivatives and their use as 5-ht6 ligands
1352011019027408/04/11Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1362011017806307/21/11Benzpyrazol derivatives as inhibitors of pi3 kinases
1372011016615007/07/11Anhydrous crystal form of ovrepitant maleate
1382011015087106/23/11Treatment of an autoimmune disease using il-18 antagonists
1392011015226206/23/11Novel compounds
1402011014282406/16/11Antibodies against amyloid-beta peptide
1412011014415106/16/11Novel process, salts, composition and use
1422011013569506/09/11Oral dosage form for controlled drug release
1432011013042306/02/11Compounds which have activity at m1 receptor and their uses in medicine
1442011011719005/19/11Pharmaceutical formulations
1452011011826105/19/11Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1462011006164603/17/11Drug dispenser
1472011006474003/17/11Antigen binding proteins
1482011006572503/17/11Triazole amide derivatives for use in therapy
1492011005916703/10/11Encapsulation of biologically active agents
1502011005997903/10/11Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1512011004502702/24/11Adjuvant
1522011004613702/24/11Pyrazole derivatives as p2x7 modulators
1532011003452402/10/11Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1542011002157801/27/11Compounds which potentiate the ampa receptor and uses thereof in medicine
1552011000939401/13/11Tricyclic nitrogen compounds and their use as antibacterial agents
1562011000963101/13/11Phenethanolamine derivatives for treatment of respiratory diseases
1572010032999612/30/10Novel combination of therapeutic agents
1582010032402212/23/10Novel compounds
1592010031657912/16/10Novel use of alkyl phosphate esters
1602010031766612/16/10Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1612010031767212/16/10Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1622010030808212/09/10Dispensing device
1632010031170612/09/10Method of treatment of allergic rhinitis
1642010031173412/09/10Spiro compounds useful as antagonists of the h1 receptor
1652010030382112/02/10Immunoglobulins
1662010030510712/02/10Quinoline derivatives and their use as 5-ht6 ligands
1672010030512712/02/10Novel compounds
1682010030516612/02/10Novel compounds
1692010029222411/18/10Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1702010029229511/18/105-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1712010028615211/11/10N-phenyl hydrazides as modulators of the ghrelin receptor
1722010027590911/04/10Actuator for an inhaler
1732010027385310/28/10Novel isoindol derivatives as ep4 receptor agonists
1742010026769110/21/10Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1752010026773410/21/10N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1762010025619910/07/10Crystalline form of an antimalarial compound
1772010025691910/07/10Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1782010023966609/23/10Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1792010022418509/09/10Actuator for an inhaler
1802010022234909/02/10Quinoline derivatives used to treat inflammatory and allergic diseases
1812010021679908/26/10Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1822010021683708/26/10Glycine transport inhibitors
1832010021067208/19/10Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1842010020325608/12/10Method and apparatus for the application of powder material to substrates
1852010020424208/12/10Piperazine derivative having affinity for the histamine h3 receptor
1862010020427308/12/10Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1872010019767908/05/10Compounds
1882010019769908/05/10I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1892010019076407/29/10Novel compounds
1902010018477007/22/10Compounds
1912010018499607/22/10Process of amide formation
1922010017569807/15/10Capsule
1932010017406507/08/10Compounds
1942010014809106/17/10Method and system for rapid phase luminescense spectroscopy analysis
1952010015219506/17/10Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1962010014401606/10/10Apparatus for the disruption of animal cells
1972010014475506/10/10Novel compounds
1982010014482906/10/10Novel receptor antagonists and their methods of use
1992010014504006/10/10Benzazepine derivatives for the treatment of neurological disorders
2002010013727606/03/10Compounds which potentiate ampa receptor and uses thereof in medicine
2012010013735306/03/10Tricyclic compounds as antibacterials
2022010013737806/03/10Pyridine compounds for the treatment of prostaglandin mediated diseases
2032010013742806/03/10Oxygen containing heterocycles as glycine transporter inhibiting compounds
2042010013058305/27/10Prolinamide derivatives as modulators of voltage-gated sodium channels
2052010011352105/06/10Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
2062010011352805/06/10Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
2072010011379605/06/10Indole derivatives as s1p1 receptor
2082010010565204/29/10Purines as cysteine protease inhibitors
2092010010568804/29/10Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
2102010010575404/29/105-(4phenyl)prolinamide for treatment of epilepsy
2112010008742404/08/10Tricyclic nitrogen containing heterocycles as antibacterial agents
2122010008750204/08/10Indazoles used to treat estrogen receptor beta mediated disorders
2132010008766704/08/10Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2142010008183004/01/10Methods of synthesizing n-hydroxysuccinimidyl carbonates
2152010007595303/25/10Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2162010007598203/25/10Pyridinone derivative for the treatment of premature ejaculation
2172010006816603/18/10Oral composition comprising dimethicone copolyol
2182010006940903/18/10"novel compounds"
2192010006941603/18/10Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2202010005905203/11/10Sheet driver for use in a drug dispenser
2212010006309703/11/10Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2222010005650203/04/10Compounds
2232010005652703/04/10Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2242010005659503/04/10Pyrazole derivatives as p2x7 modulators
2252010004863902/25/10Oxadiazole derivates as s1p1 receptor agonists
2262010004167202/18/10Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2272010002969902/04/10Matrix metalloproteinase inhibitors
2282010001628701/21/10Compounds having affinity for dopamine d3 receptor and uses thereof"
2292010001637101/21/10Indole compounds
2302010001002101/14/10Novel compounds
2312010000052801/07/10Manifold for use in medicament dispenser
2322010000052901/07/10Manifold for use in medicament dispenser
2332010000342001/07/10Medicament dispenser
2342010000423001/07/10Azatricyclic compounds and their use
2352010000424001/07/10Indole compounds
2362009032595212/31/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2372009032603212/31/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2382009031849412/24/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2392009031852312/24/09Benzoisoindole derivatives and their use as ep4 receptor agonists
2402009031853012/24/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2412009031238812/17/09Benzo [f] isoindoles as ep4 receptor agonists
2422009031254612/17/09Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2432009030605212/10/09Indenyl derivatives and use thereof for the treatment of neurological disorders
2442009029874212/03/09Process for manufacturing lactose
2452009029114611/26/09Process for manufacturing lactose
2462009029198711/26/09Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester
2472009028676211/19/09Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
2482009027560411/05/09M3 muscarinic acetylcholine receptor antagonists
2492009027035510/29/09Compounds


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo